The CBD maker said state-level changes in hemp laws as public health concerns rise are impeding attempts to expand its retail ...

Unpack the industry with the daily cannabis newsletter for business leaders.

Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

A new credit facility provided $8 million in net proceeds for growth initiatives ahead of a planned mid-2025 integration with ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

While broader real estate stocks rallied on the Federal Reserve’s latest rate cut, with the Real Estate Select Sector SPDR ...